( ALISO VIEJO Calif.--(BUSINESS WIRE)--M...)Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia,Long-Term Safety Data at AAN Annual Meeting,Health

ALISO VIEJO, Calif.--(BUSINESS WIRE)--May 1, 2007 - Avanir Pharmaceuticals (NASDAQ:AVNR) today announced that data on the long-term safety of the investigational drug Zenvia(TM) (dextromethorphan / quinidine) and the prevalence of Involuntary Emotional Expression Disorder (IEED) were presented today during a poster session at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston. The information was presented in the following posters: -0-

    1.  Poster P01.090: Involuntary Emotional Expression Disorder

        (IEED) Prevalence and Treatment


    2.  Poster P01.015: Long-Term Safety of AVP-923

        (Dextromethorphan/Quinidine) in the Treatment of Involuntary

        Emotional Expression Disorder (IEED)


    3.  Poster P01.016: Competitive Binding of Dextromethorphan to

        Selective Brain Receptor Sites

Walter Bradley, DM, FRCP, Professor and Chairman Emeritus, Department of Neurology at the University of Miami School of Medicine presented poster P01.090 "Involuntary Emotional Expression Disorder (IEED) Prevalence and Treatment." In this study a representative sample of 2318 patients in the U.S. with neurologic diseases or injuries known to cause IEED, or their caregivers, were surveyed to determine the prevalence of IEED symptoms. The results indicate that at least 1.8 million neurologic patients in the U.S. suffer from frequent and intense episodes of uncontrollable crying or laughing. In addition, the data indicate that up to 7 million neurologic patients suffer some degree of impairment caused by uncontrollable laughing or crying. Fifty nine percent of patients with IEED symptoms had discussed their symptoms with their physician and less than half received any diagnosis or treatment. The authors concluded that the prevalence of IEED in the U.S. appears to be greater than previously estimated in the medical literature and that education is needed to improve diagnosis and treatment. These data were deemed especially n
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies